Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated April 17, 2025, reports a transaction in the company's own shares. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics and Transaction Details
The filing details a share buyback executed under a programme announced on March 28, 2025. Specific transaction metrics for the purchase on April 16, 2025, are as follows:
- Shares Purchased: 856,401 ordinary shares
- Highest Price Paid: 379.40 pence per share
- Lowest Price Paid: 382.80 pence per share
- Volume Weighted Average Price: 381.35 pence per share
Following settlement, the company's registered share capital stands at 9,027,845,391 ordinary shares of £0.01 each. Of these, 4,080,205 are held as treasury shares, leaving 9,023,765,186 ordinary shares with voting rights.
Material Changes
The primary material change reported is the reduction in the number of shares with voting rights due to the cancellation of the purchased shares. The filing does not provide comparative financial data (revenue, profit, cash flow) or changes in debt and liquidity for the period.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the standard disclosure that the announcement does not constitute an offer of securities. It references the Market Abuse Regulation (EU) No 596/2014 regarding the availability of individual trade breakdowns.
Key Facts for Investor Verification
- Verify the total number of voting shares (9,023,765,186) for compliance with FCA Disclosure Guidance and Transparency Rules.
- Confirm the execution price range (379.40p - 382.80p) against the prevailing market price on April 16, 2025.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular transaction data.
- Note that this filing reports a capital transaction only and does not include operational or financial performance results.